Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8747490rdf:typepubmed:Citationlld:pubmed
pubmed-article:8747490lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8747490lifeskim:mentionsumls-concept:C0012655lld:lifeskim
pubmed-article:8747490lifeskim:mentionsumls-concept:C0023823lld:lifeskim
pubmed-article:8747490lifeskim:mentionsumls-concept:C0010055lld:lifeskim
pubmed-article:8747490lifeskim:mentionsumls-concept:C0449258lld:lifeskim
pubmed-article:8747490lifeskim:mentionsumls-concept:C0030011lld:lifeskim
pubmed-article:8747490lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:8747490pubmed:issue2lld:pubmed
pubmed-article:8747490pubmed:dateCreated1996-10-24lld:pubmed
pubmed-article:8747490pubmed:abstractTextOxidation of low-density lipoprotein (LDL) may play a causal role in atherosclerosis. In this study we analyzed whether the severity of progression of coronary atherosclerosis is related to the susceptibility of LDL to oxidative modification. On the basis of repeated coronary angiography, 28 coronary bypass patients were divided into two groups: group A, 12 patients with, and group B, 16 patients without progression of coronary atherosclerosis. The lag time, reflecting the resistance of LDL to oxidative modification, was significantly smaller in group A as compared with group B (81 +/- 10 and 93 +/- 15 min, respectively). Besides differences in cholesterol and apolipoprotein B concentrations, the difference in susceptibility of LDL to oxidation significantly contributes to the differences between the progression and the non-progression group (P = 0.02). In the combined groups of patients, the lag phase of LDL for oxidation was positively correlated with LDL cholesterol ester to protein ratio (r = 0.53, P = 0.01). It is concluded that LDL samples obtained from coronary bypass patients differ with respect to their oxidizability depending on progression of atherosclerosis following coronary bypass surgery.lld:pubmed
pubmed-article:8747490pubmed:languageenglld:pubmed
pubmed-article:8747490pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8747490pubmed:citationSubsetIMlld:pubmed
pubmed-article:8747490pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8747490pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8747490pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8747490pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8747490pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8747490pubmed:statusMEDLINElld:pubmed
pubmed-article:8747490pubmed:monthDeclld:pubmed
pubmed-article:8747490pubmed:issn0009-8981lld:pubmed
pubmed-article:8747490pubmed:authorpubmed-author:Van BerkelT...lld:pubmed
pubmed-article:8747490pubmed:authorpubmed-author:BruschkeA VAVlld:pubmed
pubmed-article:8747490pubmed:authorpubmed-author:PrincenH MHMlld:pubmed
pubmed-article:8747490pubmed:authorpubmed-author:Van Der...lld:pubmed
pubmed-article:8747490pubmed:authorpubmed-author:VerweyH FHFlld:pubmed
pubmed-article:8747490pubmed:authorpubmed-author:VogelezangC...lld:pubmed
pubmed-article:8747490pubmed:authorpubmed-author:De RijkeY BYBlld:pubmed
pubmed-article:8747490pubmed:authorpubmed-author:Van Der...lld:pubmed
pubmed-article:8747490pubmed:issnTypePrintlld:pubmed
pubmed-article:8747490pubmed:day29lld:pubmed
pubmed-article:8747490pubmed:volume243lld:pubmed
pubmed-article:8747490pubmed:ownerNLMlld:pubmed
pubmed-article:8747490pubmed:authorsCompleteYlld:pubmed
pubmed-article:8747490pubmed:pagination137-49lld:pubmed
pubmed-article:8747490pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:meshHeadingpubmed-meshheading:8747490-...lld:pubmed
pubmed-article:8747490pubmed:year1995lld:pubmed
pubmed-article:8747490pubmed:articleTitleEnhanced susceptibility of low-density lipoproteins to oxidation in coronary bypass patients with progression of atheroscerosis.lld:pubmed
pubmed-article:8747490pubmed:affiliationDivision of Biopharmaceutics Leiden-Amsterdam Center for Drug Research, University of Leiden, Netherlands.lld:pubmed
pubmed-article:8747490pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8747490pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8747490pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed